	Oncological Outcomes and Safety Profiles of Adjuvant Nivolumab in Muscle-Invasive Urothelial Carcinoma. Int J Urol Katayama S, Kawada T, Mori K, Iwatani K, Inoue S, Watanabe T, Tsuboi I, Yamanoi T, Iwata T, Tsuboi K, Murao W, Nakada T, Ogawa K, Matsukawa A, Yanagisawa T, Nishimura S, Bekku K, Wada K, Kimura T, Araki M. PMID: 42897807 [PubMed - indexed for MEDLINE]
	Medical students' knowledge, attitudes, and practices regarding renal pelvic cancer. BMC Med Educ Li Y, Feng Y, Hu S. PMID: 42897577 [PubMed - indexed for MEDLINE]
	Rare prostate cancer histologies: detection, characteristics and treatment. Nat Rev Urol Melão BVLA, Jardim DL, Li R, Collins K, Agarwal N, Grivas P, Briganti A, Necchi A, Cheng L, Spiess PE. PMID: 42897296 [PubMed - as supplied by publisher]
	Impact of Organ-Specific Severe Immune-Related Adverse Events on Long-Term Survival and Treatment Transitions in Metastatic Renal Cell Carcinoma: A 5-Year Multicenter Multistate Analysis. Cancer Med Tasaki Y, Sato K, Hamamoto S, Sugiyama Y, Ikoma H, Kawase K, Suzuki H, Noda Y, Usami M, Tsubouchi Y, Kato R, Sakata T, Tomita M, Mimura Y, Nagai T, Unno R, Etani T, Naiki T, Yasui T, Furukawa-Hibi Y. PMID: 42897107 [PubMed - indexed for MEDLINE]
	Neoadjuvant Surgical Enablement in Renal Cell Carcinoma: Systematic Review and Meta-analysis. Clin Genitourin Cancer Chai Y, Bao E, Zhong B, Zhang C, Zhang L, Jiang Y, Wang J, Liu J. PMID: 42896503 [PubMed - as supplied by publisher]
	Assessment of prostate cancer polygenic risk score in a community-based pilot study. Public Health Genomics Lin HY, Boxtha C, El-Kolalli S, Mazumder H, Denis J, O Apos Neil A, Abdulla R, Ricketts T, Alayon-Rosario G, Matta J, Park H, Chakrabarti R, Ortiz Sanchez C, Schmit S, Figueiredo J, Christy SM, Vadaparampil S, Yamoah K, Gwede CK, Park JY. PMID: 42895956 [PubMed - as supplied by publisher]
	Advances in Biomarkers and Novel Therapeutics in Renal Cell Carcinoma: Evidence from Recent Clinical Trials. Rev Recent Clin Trials John BJ, Mukherjee S, Prasad P, Adya A, Shukla R. PMID: 42895149 [PubMed - as supplied by publisher]
	Clinical Outcomes of Sequential Cabozantinib and Axitinib After First-Line Nivolumab Plus Ipilimumab in Advanced Renal Cell Carcinoma: A Single-Center Exploratory Study. Res Rep Urol Furubayashi N, Kojima T, Nakano Y, Kataoka A, Negishi T. PMID: 42894711 [PubMed]
	Differentiating Xp11.2/TFE3 translocation renal cell carcinoma from clear cell carcinoma: performance of a radiomics model. BMC Cancer Liu Y, Wang K, Zhang Y, Liu J, Xi Z, Wang X, Yu Y, Wang X. PMID: 42894154 [PubMed - indexed for MEDLINE]
	A prospective randomized controlled trial comparing subpectineal and interfascial obturator nerve block techniques in preventing adductor muscle spasm during transurethral resection of bladder tumors. BMC Anesthesiol Sayg, Köse HC, Köse SG, Akkaya ÖT. PMID: 42894134 [PubMed - indexed for MEDLINE]
	Diagnostic performance and pathologic associations of the UroVysion assay in patients with upper tract lesions and negative urinary cytology: a large-scale real-world study of 1,256 patients. World J Urol Zheng L, Guan B, Wu Z, Ding Y, Zhang B, Li X, Gong Y. PMID: 42894019 [PubMed - indexed for MEDLINE]
	Segment-based comparison of multiparametric MRI, Gallium-68-PSMA-PET/CT and combined imaging with histopathology in prostate cancer. BJU Int Schmidt CJ, Bernhardt M, Kristiansen G, Gaertner FC, Kreppel B, Essler M, Luetkens JA, Attenberger U, Anspach M, Ohlmann CH, Hauser S, Ellinger J, Ritter M, Krausewitz P. PMID: 42893832 [PubMed - as supplied by publisher]
	Bladder Urothelial Carcinoma Diagnosed by Perineal Cutaneous Biopsy: A Case Report. Cureus Guiu RJ, Dias GC, Silva PH, Ferreira MA, Ventura GR. PMID: 42893157 [PubMed]
	Adjuvant Systemic Therapies After Nephrectomy for Renal Cell Carcinoma: A Bayesian Network Meta-Analysis and Multi-Criteria Benefit-Risk Assessment. Target Oncol Yajima S, Okumura G, Yoshida S, Fukushima H, Sato H, Hirakawa A, Kijima T, Masuda H, Fujii Y. PMID: 42892667 [PubMed - as supplied by publisher]
	Qualitative study on barriers and facilitators to genetic testing in Hispanic patients with prostate cancer. Prostate Cancer Prostatic Dis Chebli P, Sanchez Nolasco T, Rangel Camacho M, Byrne N, Giri VN, Vadaparampil ST, Loeb S. PMID: 42892630 [PubMed - as supplied by publisher]
	Comparison of cardiovascular events in patients with metastatic hormone sensitive prostate cancer treated with LHRH agonists to LHRH antagonists in the US: A retrospective cohort study. Urol Oncol Titus RS, Velasquez EL, Mundra V, Riveros C, Ranganathan S, Nguyen DD, Singh A, Porika A, Kaushik D, Patel KV, Efstathiou E, Wallis CJD, Satkunasivam R. PMID: 42892580 [PubMed - as supplied by publisher]
	Incidence and predictors of prolonged opioid use following nephrectomy for renal cell carcinoma: A national claims-based study. Urol Oncol Esen B, Lahiji R, Patil D, Luke W, Mumford S, Landrum KR, Ramacciotti LS, Nabavizadeh R, Hajiha M, Grajales V, Joshi SS, Narayan VM, Ogan K, Master VA. PMID: 42892579 [PubMed - as supplied by publisher]
	Restricted mean survival time-based network meta-analysis of first-line therapies for metastatic clear cell renal cell carcinoma. Urol Oncol McGrath J, Johnson K, Hakam N, Venkatesh A, Ishiyama Y, Metzner T, Balaji KC. PMID: 42892578 [PubMed - as supplied by publisher]
	Individual and mixed urinary trace metal exposures and their associations with prostate cancer in Tanzania: A case-control study using BKMR. Environ Toxicol Pharmacol Njale E, Mahugija JAM, Shilla DJ. PMID: 42892537 [PubMed - as supplied by publisher]
	Analysis of quality-adjusted time without symptoms or toxicity (Q-TWiST) in patients with metastatic hormone-sensitive prostate cancer from the ARASENS trial. Eur J Cancer Maiorano BA, Smith MR, Hussain M, Saad F, Tombal B, Sternberg CN, Mohamed AF, Dissanayake M, Moscovici M, Verholen F, Kuss I, Fizazi K. PMID: 42892235 [PubMed - as supplied by publisher]

Articles 1 - 20 / 182268

Page 1 of 9114



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy